Clinical Guidelines for Hepatic Artery Disorders

Abstract

Hepatic artery disorders represent a spectrum of vascular abnormalities affecting the hepatic arterial system, with significant implications for hepatic perfusion, liver function, and patient outcomes. This review synthesizes current clinical guidelines, recent research, and expert consensus to provide a comprehensive, evidence-based approach to the diagnosis, management, and follow-up of hepatic artery disorders. Focus is given to epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic strategies, therapeutic interventions, and recent advances, with a particular emphasis on practical and mechanism-based recommendations for clinical practice.

Introduction

Hepatic artery disorders encompass various pathological entities, including hepatic artery aneurysm, stenosis, thrombosis, and iatrogenic injuries. These conditions, while relatively rare compared to other hepatic vascular pathologies, can lead to significant morbidity and mortality, particularly in the context of liver transplantation, trauma, or underlying liver disease. Recent advances in vascular imaging, endovascular therapies, and surgical techniques have transformed the clinical landscape, necessitating updated, evidence-based guidelines for optimal patient care. This article provides an in-depth review of hepatic artery disorders for healthcare professionals, with a focus on integrating mechanistic insights and guideline-driven recommendations into real-world clinical practice.

Epidemiology / Disease Burden

Hepatic artery aneurysms, the second most common visceral artery aneurysms after splenic, have an estimated incidence of 0.002% to 0.4% in autopsy series. The true prevalence may be underreported due to asymptomatic cases. Hepatic artery stenosis and thrombosis are particularly significant in the post-liver transplantation population, with hepatic artery thrombosis (HAT) reported in 2%-9% of adult transplant recipients, representing a leading cause of graft failure. Iatrogenic injury, especially during cholecystectomy or biliary interventions, has contributed to an increased procedural burden. The disease burden is compounded by the risk of catastrophic complications such as hepatic infarction, abscess, or hemorrhage, which underscore the importance of early recognition and management.

Pathophysiology

The hepatic arterial system is characterized by a dual blood supply to the liver, with the hepatic artery providing oxygen-rich arterial blood and the portal vein delivering nutrient-rich venous blood. Disruption of hepatic arterial flow, as seen in thrombosis or severe stenosis, compromises the oxygenation of bile ducts and liver parenchyma, predisposing to ischemic cholangiopathy, biliary strictures, or hepatic necrosis. Aneurysm formation is driven by degenerative changes in the arterial wall, atherosclerosis, trauma, infection (mycotic aneurysms), or connective tissue disorders. Iatrogenic injuries typically involve laceration or ligation, leading to acute ischemic consequences. The pathophysiological sequelae are dictated by the rapidity, extent, and location of arterial compromise, as well as compensatory collateralization.

Risk Factors

Risk factors for hepatic artery disorders vary by entity. Atherosclerosis, hypertension, and connective tissue disorders (e.g., Ehlers-Danlos, Marfan syndrome) predispose to aneurysm formation. Liver transplant recipients are at elevated risk for hepatic artery stenosis and thrombosis, influenced by surgical technique, recipient vascular anatomy, rejection episodes, and prothrombotic states. Trauma, both external and iatrogenic, is a significant risk factor for acute arterial injury. Chronic biliary disease, systemic infection, and systemic vasculitis also contribute to the risk landscape. Understanding these risk factors aids in stratifying patients for surveillance and prophylactic intervention.

Clinical Features

Clinical presentation ranges from asymptomatic incidental findings to acute life-threatening events. Hepatic artery aneurysms may present with nonspecific abdominal pain or, more ominously, with rupture causing intra-abdominal hemorrhage and shock. Hepatic artery stenosis or thrombosis often manifests as abnormal liver function tests, biliary complications (e.g., bile leaks, strictures), or graft dysfunction in transplant recipients. Iatrogenic injuries typically present acutely post-procedure with hepatic ischemia, abdominal pain, or hemodynamic instability. Given the non-specificity of symptoms, high clinical suspicion is required, especially in at-risk populations.

Diagnosis

Diagnosis is primarily reliant on imaging modalities. Doppler ultrasonography serves as a frontline tool, particularly in post-transplant surveillance, allowing for assessment of hepatic arterial patency and flow dynamics. Contrast-enhanced computed tomography angiography (CTA) and magnetic resonance angiography (MRA) provide detailed anatomical and functional information, facilitating the identification of aneurysms, stenoses, or occlusions. Digital subtraction angiography (DSA) remains the gold standard for definitive diagnosis and interventional planning, particularly in cases requiring endovascular therapy. Laboratory investigations may assist in monitoring hepatic function but are non-specific for vascular disorders.

Treatment & Management

The therapeutic approach is dictated by the specific disorder, clinical context, and risk of complications. Asymptomatic, small hepatic artery aneurysms may be monitored, whereas symptomatic or large aneurysms, or those at risk of rupture, warrant prompt intervention. Endovascular techniques, such as coil embolization or covered stent placement, have become first-line therapies due to lower morbidity compared to open surgery. Surgical revascularization or aneurysmectomy is reserved for complex or ruptured cases. Management of hepatic artery stenosis or thrombosis post-transplant includes percutaneous transluminal angioplasty, stenting, or surgical revision. Anticoagulation, while controversial, may be considered in selected cases. Multidisciplinary management is essential, especially in transplant recipients and those with complex anatomy or comorbidities.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in endovascular technology, including drug-eluting stents, flow-diverting devices, and bioresorbable scaffolds, enhancing the safety and efficacy of minimally invasive treatments. Intraoperative fluorescence imaging and 3D navigation have improved surgical precision. Novel biomarkers and imaging techniques are under investigation for earlier detection of vascular complications post-transplant. In the arena of transplantation, improved surgical techniques, tailored immunosuppression, and standardized post-operative monitoring protocols have contributed to reduced incidence and improved outcomes of hepatic artery disorders.

Guideline Recommendations

Current guidelines, including those from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), emphasize early identification and intervention for hepatic artery disorders. Regular Doppler ultrasound surveillance is recommended for liver transplant recipients. Endovascular intervention is preferred for aneurysms and stenotic lesions when feasible, with surgical management reserved for refractory or anatomically complex cases. Multidisciplinary collaboration, prompt recognition of clinical deterioration, and individualized risk stratification are critical. Guidelines also advocate for the optimization of cardiovascular risk factors and strict perioperative vigilance to minimize iatrogenic injuries.

Conclusion

Hepatic artery disorders, though uncommon, pose significant diagnostic and therapeutic challenges with profound clinical implications, particularly in the context of liver transplantation and hepatic surgery. Advances in imaging and endovascular interventions have improved outcomes, but early recognition, risk stratification, and adherence to clinical guidelines remain paramount. Ongoing research into emerging therapies and improved surveillance strategies will continue to inform and refine clinical practice, ultimately enhancing patient care and prognosis in this complex domain.